glp 1 and blindness A warning about GLP-1 that many people may not have heard about. David Sinclair points to research from Harvard ophthalmologist Dr. Joseph Rizzo suggesting a possible connection between GLP-1 medications NAION—a GLP-1 Receptor Agonists in Jars:1 Jar delivery_badge

glp 1 and blindness A warning about GLP-1 that many people may not have heard about. David Sinclair points to research from Harvard ophthalmologist Dr. Joseph Rizzo suggesting a possible connection between GLP-1 medications NAION—a GLP-1 Receptor Agonists in Jars:1 Jar delivery_badge

GLP-1 Receptor Agonists in Obese Patients with Inflammatory Bowel Disease: from Molecular Mechanisms to Clinical Considerations and Practical Recommendations for Safe and Effective Use | Current Obesity Reports | Springer Nature Link

Nevertheless, the consistency of preclinical findings has fueled optimism that GLP-1–based therapies may ultimately find uses far beyond diabetes and obesity

delivery_badge

Jars:1 Jar

Boehringer Ingelheim focuses on pharmaceutical research and advanced drug development technologies